-+ 0.00%
-+ 0.00%
-+ 0.00%

Shisi Pharmaceutical Group (02005): Bevanolol hydrochloride has been approved and registered as an API for use in marketed formulations

Zhitongcaijing·11/13/2026 10:01:05
Listen to the news

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) announced that the group's bevanolol hydrochloride has been approved by the China National Drug Administration to register as an active ingredient for use in marketed formulations, and is the third domestic company to be approved.

Bevanolol hydrochloride is mainly used to treat underlying hypertension. It is a new generation of highly selective α1+beta1 dual blockers. On the one hand, it blocks cardiac β1 receptors, smoothly slows heart rate and reduces myocardial contractility; on the other hand, it blocks vascular α1 receptors, directly dilates peripheral blood vessels, reduces vascular resistance, and inhibits renin release. It can achieve stable pressure control for 24 hours. It is a novel antihypertensive drug with a fully upgraded mechanism.